Menu
Back to Journals » Biologics: Targets and Therapy » Volume 3
Current available therapies and future directions in the treatment of malignant gliomas
Authors Desjardins A, Reardon DA, Vredenburgh J
Published 17 December 2008 Volume 2009:3 Pages 15—25
DOI https://doi.org/10.2147/BTT.S3098
Review by Single anonymous peer review
Peer reviewer comments 7
Annick Desjardins1,2, David A Reardon1,3, James J Vredenburgh1,2
1The Preston Robert Tisch Brain Tumor Center; 2Department of Medicine; 3Department of Surgery, Duke University Medical Center, Durham, NC, USA
Abstract: The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and signal transduction pathway targets have been identified that are now being investigated. Novel locoregional treatments, as well as strategies to improve regional delivery, are being evaluated. Studies of combinations of these approaches are also underway. In this review, we will discuss the current and future therapies under evaluation for the treatment of malignant gliomas.
Keywords: glioma, glioblastoma, targeted therapy, kinase inhibitor
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.